Postmortem brain levels of urate and precursors in parkinson's disease and related disorders

Neurodegenerative Diseases

Volumn 12, Issue 4, 2013, Pages 189-198

  McFarland, Nikolaus R ^a,b   Burdett, Thomas ^b   Desjardins, Cody A ^b   Frosch, Matthew P ^b,c   Schwarzschild, Michael A ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Neurology ^*  (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Lewy body disease; Neurodegeneration Parkinsonism; Purines; Uric acid

Indexed keywords

ADENOSINE; HYPOXANTHINE; INOSINE; URATE; XANTHINE; PURINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DEATH; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DRUG BRAIN LEVEL; ELECTROCHEMICAL DETECTION; FEMALE; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TEMPORAL CORTEX; ULTRAVIOLET RADIATION; AUTOPSY; BRAIN LEVEL; BRAIN REGION; BRAIN TISSUE; DEGENERATIVE DISEASE; MAJOR CLINICAL STUDY; RADIATION DETECTION; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INOSINE; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; POSTMORTEM CHANGES; PURINES; REGRESSION ANALYSIS; SEX FACTORS; SIGNAL TRANSDUCTION; URIC ACID; XANTHINE;

EID: 84887058680     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000346370     Document Type: Article

References (41)

1. Oda M, Satta Y, Takenaka O, Takahata N: Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002; 19: 640-653. (Pubitemid 34521296)
2. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant-and radicalcaused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-6862. (Pubitemid 12216861)
3. Yeum KJ, Russell RM, Krinsky NI, Aldini G: Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys 2004; 430: 97-103. (Pubitemid 39119784)
4. Proctor P: Similar functions of uric acid and ascorbate in man? Nature 1970; 228: 868.
5. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53(Suppl 3):S26-S36; discussion S36-S38.
6. Beal MF: Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58: 495-505. (Pubitemid 41377212)
7. Church WH, Ward VL: Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994; 33: 419-425.
8. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM: Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005; 58: 797-800. (Pubitemid 41552559)
9. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007; 166: 561-567. (Pubitemid 47283643)
10. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J: Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008; 65: 716-723. (Pubitemid 351831449)
11. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU: Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 344-348.
12. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P: Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003; 24: 915-919. (Pubitemid 36962976)
13. Bigio EH: C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. Acta Neuropathol 2011; 122: 653-655.
14. Auinger P, Kieburtz K, McDermott MP: The relationship between uric acid levels and Huntington's disease progression. Mov Disord 2010; 25: 224-228.
15. Lee JE, Song SK, Sohn YH, Lee PH: Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 2011; 26: 1533-1536.
16. Euser SM, Hofman A, Westendorp RG, Breteler MM: Serum uric acid and cognitive function and dementia. Brain 2008; 132: 377-382.
17. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS: Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009; 6: 23-28.
18. Vannorsdall TD, Jinnah HA, Gordon B, Kraut M, Schretlen DJ: Cerebral ischemia mediates the effect of serum uric acid on cognitive function. Stroke 2008; 39: 3418-3420.
19. Daniel SE, Lees AJ: Parkinson's disease society brain bank, London: overview and research. J Neural Transm Suppl 1993; 39: 165-172. (Pubitemid 23216938)
20. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39. (Pubitemid 29046907)
21. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M: Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65: 1863-1872. (Pubitemid 43970103)
22. Hyman BT, Trojanowski JQ: Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. J Neuropathol Exp Neurol 1997; 56: 1095-1097.
23. Grootveld M, Halliwell B: Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo? Biochem J 1987; 243: 803-808.
24. Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA: Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed Chromatogr 2013; 27: 122-129.
25. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA: Uric acid and the development of hypertension: the normative aging study. Hypertension 2006; 48: 1031-1036. (Pubitemid 44772704)
26. Sato M, Wakayama T, Mamada H, Shirasaka Y, Nakanishi T, Tamai I: Identification and functional characterization of uric acid transporter Urat1 (Slc22a12) in rats. Biochim Biophys Acta 2011; 1808: 1441-1447.
27. Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum 2011; 63: 3136-3141.
28. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA: Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460-1468.
29. O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A: Plasma urate and Parkinson's disease in women. Am J Epidemiol 2010; 172: 666-670.
30. Benzie IF, Chung W, Tomlinson B: Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies. Clin Chem 1999; 45: 901-904. (Pubitemid 29266623)
31. Ruggiero C, Cherubini A, Lauretani F, Bandinelli S, Maggio M, Di Iorio A, Zuliani G, Dragonas C, Senin U, Ferrucci L: Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord 2009; 27: 382-389.
32. Schretlen DJ, Inscore AB, Jinnah HA, Rao V, Gordon B, Pearlson GD: Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 2007; 21: 136-140. (Pubitemid 46066213)
33. Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon B, Jinnah HA: Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423. (Pubitemid 47511463)
34. Londos E, Passant U, Brun A, Gustafson L: Clinical Lewy body dementia and the impact of vascular components. Int J Geriatr Psychiatry 2000; 15: 40-49. (Pubitemid 30087913)
35. Maetzler W, Schafer A, Schulte C, Hauser AK, Lerche S, Wurster I, Schleicher E, Melms A, Berg D: Serum and cerebrospinal fluid uric acid levels in Lewy body disorders: associations with disease occurrence and amyloid-? pathway. J Alzheimers Dis 2011; 27: 119-126.
36. Alonso A, Rodriguez LA, Logroscino G, Hernan MA: Gout and risk of Parkinson disease: a prospective study. Neurology 2007; 69: 1696-1700. (Pubitemid 350287126)
37. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, Vassilopoulos D: Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 2009; 111: 724-728.
38. Chen H, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 1009; 169: 1064-1069.
39. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators: Serum urate and probability of dopaminergic deficit in early 'Parkinson's disease'. Mov Disord 2011; 26: 1864-1868.
40. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
41. Cipriani S, Chen X, Schwarzschild MA: Urate: A novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 2010; 4: 701-712.